CLDX — Celldex Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Life Sciences Tools & Services ·
CIK 744218 ·
Last close
$38.06
Market Cap
$2.99B
52W High
$40.30
52W Low
$28.38
ADV30
1,233,683
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 15,000 | — | -84,435,000 | -78,685,000 | 511,254,000 | 35,729,000 | 55,028,000 |
| Dec 2025 | 121,000 | — | -87,153,000 | -81,317,000 | 582,983,000 | 28,871,000 | 55,818,000 |
| Sep 2025 | 0 | — | -73,617,000 | -67,044,000 | 648,439,000 | 36,037,000 | 50,076,000 |
| Jun 2025 | 730,000 | — | -63,857,000 | -56,600,000 | 692,407,000 | 23,044,000 | 37,001,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-210,945,000
Investing CF
$209,072,000
Financing CF
$2,388,000
CapEx
$-2,714,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.89
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,813,981,000
Inventory
—
Receivables
$2,015,000
ST Investments
$489,702,000
EBIT TTM
$-287,366,000
Pretax Income TTM
$-258,757,000
Interest Exp TTM
—
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$865,000
EBITDA
$-305,696,000
Free Cash Flow
$-126,271,376
Enterprise Value
$2,537,858,304
Total Cash
$451,457,984
Total Debt
$1,908,000
Shares Out
78,492,072
Trailing EPS
$-4.27
Book Value
$6.85
ROE
-48.9%
ROA
-30.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 1,545,000 | -287,367,000 | -258,757,000 | 582,983,000 | 55,818,000 | — | -210,945,000 |
| Dec 2024 | 7,020,000 | -195,078,000 | -157,863,000 | 792,340,000 | 45,335,000 | — | -157,778,000 |
| Dec 2023 | 6,883,000 | -142,042,000 | -141,429,000 | 465,627,000 | 36,456,000 | — | -107,291,000 |
| Dec 2022 | 2,357,000 | -107,096,000 | -112,325,000 | 352,735,000 | 26,531,000 | — | -103,732,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.37
Max Pain — expiry 2026-12-18
max pain strike: $37.00 · spot: $38.06 · call oi: 1,099 · put oi: 3,310
Expected Move to 2026-12-18:
±$26.35
(69.23%) —
implied range
$11.71 –
$64.41
· ATM straddle on $38.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NEOG | NEOGEN CORP | $2.63B | $12.04 | — |
| NTLA | Intellia Therapeutics, Inc. | $1.49B | $10.68 | — |
| LNTH | Lantheus Holdings, Inc. | $6.49B | $99.64 | — |
| ABSI | Absci Corp | $1.32B | $7.78 | — |
| QDEL | QuidelOrtho Corp | $1.14B | $16.77 | — |
News headlines (Yahoo Finance, 1h cache)
Are Medical Stocks Lagging Celldex Therapeutics (CLDX) This Year?
2026-07-24 13:40 · Yahoo
Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss
2026-07-22 10:02 · Yahoo
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
2026-07-22 09:33 · Yahoo
CLDX Stock Down 10% After-Hours — What’s Driving The Selloff?
2026-07-21 22:52 · Yahoo
Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis
2026-07-21 20:01 · Yahoo
Eton Pharmaceuticals (ETON) Moves 13.8% Higher: Will This Strength Last?
2026-07-20 11:26 · Yahoo
Celldex Announces Planned Transition of Chief Financial Officer
2026-07-15 20:01 · Yahoo
Is Celldex Therapeutics, Inc. (CLDX) Stock Positioned for Growth Ahead of Potential 2027 Approval?
2026-06-30 13:21 · Yahoo
Chronic Spontaneous Urticaria Market Heats Up as Pharma Companies Race to Address Unmet Needs | DelveInsight
2026-06-24 14:31 · Yahoo
QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now
2026-06-19 12:24 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.